Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411898 | 1.00 | GLS (0.74) | GLS | |
| SCHEMBL17396806 | 1.00 | GLS (0.74) | GLS | |
| SCHEMBL17412292 | 0.91 | GLS (0.73) | GLS | |
| SCHEMBL17419927 | 0.91 | GLS (0.73) | GLS | |
| SCHEMBL17427976 | 0.90 | GLS (0.78) | GLS | |
| SCHEMBL17412330 | 0.90 | GLS (0.69) | GLS | |
| SCHEMBL29752700 | 0.90 | GLS (0.69) | GLS | |
| SCHEMBL20932909 | 0.89 | GLS (0.75) | GLS | |
| SCHEMBL19558973 | 0.89 | GLS (0.68) | GLS | |
| SCHEMBL29752750 | 0.88 | GLS (0.77) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164195-B1 | GLUTAMINASE INHIBITOR THERAPY | UNIV TEXAS (US) | 2022-06-15 | — | — | EP | claimed |
| US-11045443-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | claimed |
| US-20200368196-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-26 | — | — | US | claimed |
| US-10722487-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-07-28 | — | — | US | claimed |
| US-20190274993-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-12 | — | — | US | claimed |
| US-12336976-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-24 | — | — | US | disclosed |
| EP-3697764-B1 | GLS-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIV TEXAS (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-20240165070-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-23 | — | — | US | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-11786500-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786500-B2 | Glutaminase inhibitor therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-17 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| EP-3164394-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | Board of Regents, The University of Texas System (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160058759-A1 | GLUTAMINASE INHIBITOR THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190274993-A1 | GLUTAMINASE INHIBITOR THERAPY | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-20200368196-A1 | GLUTAMINASE INHIBITOR THERAPY | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-12336976-B2 | Glutaminase inhibitor therapy | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-20160058759-A1 | GLUTAMINASE INHIBITOR THERAPY | GLS, GLS2, KEAP1 | GLS 1/4885 |
| US-20240165070-A1 | GLUTAMINASE INHIBITOR THERAPY | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-10722487-B2 | Glutaminase inhibitor therapy | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | GLS 2/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | GLS 2/4885 |
| US-11786500-B2 | Glutaminase inhibitor therapy | ASNS, GLS, GLS2 | GLS 2/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | GLS 2/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | GLS 2/4885 |
| US-11045443-B2 | Glutaminase inhibitor therapy | ASNS, GLS, GLS2 | GLS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.